MET and osteosarcoma: A Phase II study of cabozantinib (which targets VEGFR-2, the AXL receptor tyrosine kinase, and c-MET) in 42 patients with heavily pretreated, advanced osteosarcoma reported a median PFS of 6.2 months [12].